A
Alcista
Alcista · 25%SPRC
$7.05
Precio del escenario
$1.090
-0.100 (-9.17%)Al cierre
Loading chart…
- Máximo
- 1.210
- Apertura
- 1.210
- Precio medio ponderado por volumen
- 1.12
- Volumen
- 6.00M
- Capitalización
- 2.77M
- Mínimo
- 1.070
- Importe
- 6.74M
- EV/EBITDA, TTM
- 0.00
Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Análisis de IA of Scisparc Ltd (SPRC)
VenderSciSparc Ltd. is not a good buy right now due to its significant recent losses and negative financial indicators. The stock has dropped 91.35% year-to-date and has a current price of $1.09, which is far below its historical performance. Additionally, the RSI is extremely low at 5.451, indicating that the stock is oversold and may continue to decline. The company also reported a net margin of -2041.65% in Q2 2025, highlighting severe profitability issues. The main risk is the ongoing decline in stock price, with a 5-day change of -35.88%.
Métricas de valoración
El PER previsto actual de Scisparc Ltd (SPRC) es 0.00, frente a su media de 5 años de -7.26.
Escenarios de precio de Alphio AI para SPRC
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
9.010-22NewsfilterSciSparc's Subsidiary Advances Tourette Syndrome Clinical Trial
- 4.510-19Newsfilter
SciSparc Shifts Strategic Focus to Agentic AI Technologies
- 4.510-15Newsfilter
SciSparc Shifts Strategic Focus to Agentic AI Technologies
- 8.509-02Newsfilter
NeuroThera Pursues FDA Orphan Drug Designation for SCI-110
- 4.508-26Newsfilter
SciSparc Appoints AI Expert to Strengthen Strategic Focus
Preguntas frecuentes sobre SPRC, respondidas por Alphio AI
Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
SciSparc Ltd. is not a good buy right now due to its significant recent losses and negative financial indicators. The stock has dropped 91.35% year-to-date and has a current price of $1.09, which is far below its historical performance. Additionally, the RSI is extremely low at 5.451, indicating that the stock is oversold and may continue to decline. The company also reported a net margin of -2041.65% in Q2 2025, highlighting severe profitability issues. The main risk is the ongoing decline in stock price, with a 5-day change of -35.88%.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.